The American Journal of Psychiatry
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Full Text
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
* Citation Map
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via HighWire
* Citing Articles via Google Scholar
Google Scholar
* Articles by Luchins, D. J.
* Articles by Harris, J.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by Luchins, D. J.
* Articles by Harris, J.
Am J Psychiatry 155:365-366, March 1998
© 1998 American Psychiatric Association


Regular Article

Alteration in the Recommended Dosing Schedule for Risperidone

Daniel J. Luchins, M.D., David Klass, M.D., Patricia Hanrahan, Ph.D., Randy Malan, R.Ph., and John Harris, M.A.

OBJECTIVE: The authors' goal was to study the recommended dose schedule for risperidone. METHOD: They obtained computerized pharmacy data on 1,283 inpatients with the diagnoses of schizophrenia or schizoaffective disorder who were treated with risperidone. Continuance on risperidone was defined as remaining on the drug for 16 days or until discharge. RESULTS: The majority of the patients (84%) continued on risperidone. Use of the recommended dose schedule decreased greatly over time. Patients were more likely to continue on risperidone if they had a higher maximum dose (5.7 mg/day versus 4.7 mg/day), a longer number of days to maximum dose (5.7 days versus 3.9 days), and a maximum rise in dose of 0.5–2 mg/day. CONCLUSIONS: These findings suggest that the recommended dose schedule should be altered to one that recommends a less rapid titration (over 6 days to a week) and that the dose increments consist of 0.5–2 mg/day.




This article has been cited by other articles:


Home page
J PsychopharmacolHome page
N. Ezewuzie and D. Taylor
Establishing a dose-response relationship for oral risperidone in relapsed schizophrenia
J Psychopharmacol, January 1, 2006; 20(1): 86 - 90.
[Abstract] [PDF]


Home page
J PsychopharmacolHome page
P. J. Weiden
Switching antipsychotics: an updated review with a focus on quetiapine
J Psychopharmacol, January 1, 2006; 20(1): 104 - 118.
[Abstract] [PDF]


Home page
Am. J. PsychiatryHome page
V. P. KONTAXAKIS, B. J. HAVAKI-KONTAXAKI, S. S. STAMOULI, and G. N. CHRISTODOULOU
Optimal Risperidone Dose in Drug-Naive, First-Episode Schizophrenia
Am J Psychiatry, July 1, 2000; 157(7): 1178- - 1179.
[Full Text]


Home page
Am. J. PsychiatryHome page
R. PIES
Individualized Risperidone Dosing
Am J Psychiatry, July 1, 1999; 156(7): 1123a - 1124.
[Full Text]


Home page
JWatch PsychiatryHome page
New Dosing Recommended for Risperidone
Journal Watch Psychiatry, May 1, 1998; 1998(501): 4 - 4.
[Full Text]




Get information about faster international access.

Privacy Policy

Copyright © 1998 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. American Psychiatric Association
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org